Navigation Links
Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
Date:5/4/2009

-Preliminary Data from This Trial to be Presented at ASCO-

-First Phase II Trial in Bavituximab Cancer Program to Complete Patient Enrollment-

TUSTIN, Calif., May 4 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it has completed enrollment in its Phase II trial evaluating bavituximab in combination with docetaxel in advanced breast cancer patients. The planned 46 patients have been enrolled and are currently undergoing treatment and follow-up. The primary objective of the multi-center, open-label Phase II study is to assess the overall response rate to bavituximab and docetaxel. The company also announced that preliminary data from this trial has been accepted for oral presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.

"Completion of patient enrollment in this Phase II study in advanced breast cancer patients represents a milestone for Peregrine's bavituximab cancer program, as this is the first of our three ongoing Phase II cancer trials to complete patient enrollment," said Steven W. King, president and CEO of Peregrine. "We will continue to assess patients in this study over the coming months and look forward to reporting updated preliminary results from the trial at the upcoming ASCO Annual Meeting."

In this trial's Simon two-stage design, 15 patients with advanced breast cancer were enrolled in the trial's first cohort. Ten of the 14 evaluable patients in this cohort demonstrated an objective tumor response according to RECIST criteria. These results compare favorably with historical response rates for docetaxel as solo therapy in advanced breast cancer patients and exceeded the pre-specified primary efficacy endpoint needed to expand enrollment in the trial. An additional 31 patients were then enrolled to achieve the planned study total of 46 patients overall.

Secondary obj
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
2. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
3. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
4. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
5. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
6. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
10. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
11. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015   Physicians Rx ... Bernstein has joined the organization as President and ... recently served as President and Chief Executive Officer for ... Chief Executive Officer of Physicians Rx Pharmacy, be responsible ... "We are extremely pleased to bring Gaston on ...
(Date:9/2/2015)... , Sept. 2, 2015 Research and Markets ... "Inhaled Drug Delivery (London, UK - November 19-20, ... Inhaled Drug Delivery meeting will cover industry case studies, ... more. The Co-Chairmen are Dr Steven Nichols , ... Director, Mylan. Companies participating include: ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hcb7bz/pharmaceutical ) has announced the addition of ... 16-18, 2015)" conference to their offering. Regulatory requirements for ... Peru , Brazil , ... , Paraguay , Venezuela , ... Chile This seminar can be viewed both as ...
Breaking Medicine Technology:Gaston L. Bernstein Named President and CEO of Physicians Rx Pharmacy 2Pharmaceutical Regulatory Affairs in Latin America Seminar - London, UK - November 16-18, 2015 2
... ULURU Inc. (NYSE Amex: ULU ) today ... fourth quarter and year ended 2010 financial results and to provide ... a.m. Eastern Time. To participate in the conference call ... code 23750#) five to ten minutes prior to the initiation of ...
... The Food and Drug Administration (FDA) today approved the use ... of shingles in individuals 50 to 59 years of age. ... of age and older. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... 200,000 healthy people between the ages of 50 and 59, ...
Cached Medicine Technology:ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2010 and to Provide a Business Update 2FDA Approves Zostavax Vaccine to Prevent Shingles in Individuals 50 to 59 Years of Age 2
(Date:9/3/2015)... ... ... Local filmmakers and now co-hosts of the up and coming podcast Path11 Podcast ... great success in launching their Path11 Podcast with 23 episodes released since April 2015. ... the well known Spiritual Catalyst and Linda Howe, leader in the field of Akashic ...
(Date:9/3/2015)... ... September 03, 2015 , ... Doctor Kayode Sotonwa can ... professionals out there. His perspective on internal medicine keeps patients happy and healthy, something ... is important regardless of the season, but even more so in the fall, when ...
(Date:9/2/2015)... ... , ... The Aspen Clinic (TAC), located in Basalt, Colorado, today ... inspiring wellness in the Roaring Fork Valley and beyond. , Amanda Wagner, Executive Director ... to fitness - we are much more than a gym. Our fitness and ...
(Date:9/2/2015)... ... September 03, 2015 , ... ... University Bloomberg School of Public Health and an internationally recognized scholar on obesity ... for 2015-16. Dr. Bleich, a Baltimore native and 1996 graduate of Garrison Forest ...
(Date:9/2/2015)... ... September 02, 2015 , ... Chris Harrison of Harrison’s Footwear of ... a simple decision, really,” says Chris. “We have a lot of repeat customers, and ... that work best for them—so we’ve given them the convenience of ordering from home.” ...
Breaking Medicine News(10 mins):Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 2Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 3Health News:Doctor Kayode Sotonwa Highlights Expert Tips for Staying in Shape This Fall 2Health News:TAC Introduces New Retreats for Fall Fitness 2Health News:Dr. Sara Bleich, Garrison Forest Graduate, Selected for 2015-16 Class of White House Fellows 2Health News:Harrison's Comfort Footwear Announces Expansion with New CHarrison Online Store 2
... study says , , TUESDAY, Feb. 12 (HealthDay News) -- Americans ... pain, but new research suggests those extra dollars aren,t buying ... the authors of a study in the Feb. 13 issue ... but the lack of results weren,t. , "This calls into ...
... parent of Northwestern Memorial Hospital, appointed,at its January ... Northwestern,Memorial Foundation,s Boards of Directors., Trina D. ... of the Friends of Prentice,board of directors and ... Committee. Gordon is chairman of Boyden World,Corporation,s board ...
... 12 NHS Choices ( http://www.nhs.uk ),the online ... interactive tool aimed,to help people better understand the ... NHS accredited information, the food allergy symptom checker,( ... whether they have either a food allergy or ...
... The recent influenza,outbreaks across the country, resulting in at ... reminder that the influenza virus is a serious disease,and ... influenza hospitalizes more than 20,000 children,younger than 5 years ... and causes,approximately 100 deaths. These statistics are particularly tragic ...
... Feb. 12 A proposed,regulation to improve the ... by fostering the establishment of Patient Safety Organizations,(PSOs) ... Health and Human,Services (HHS)., PSOs are private ... patient safety events reported by health care providers. ...
... jaw adjustment, BLOOMINGTON, Ind., Feb. 12 A ... Medicine is advocating for the medical,community to provide relief ... sometimes deadly sleep apnea by using a common and ... just amazing that a few millimeters of adjustment, bringing ...
Cached Medicine News:Health News: Back Pain Spending Up, Relief Down 2Health News: Back Pain Spending Up, Relief Down 3Health News:Northwestern Memorial HealthCare and Northwestern Memorial Foundation Elect New Members to Board of Directors 2Health News:Childhood Influenza Immunization Coalition Responds to Recent Influenza Outbreaks 2Health News:New Patient Safety Proposed Regulation Aims to Improve Health Care Quality and Patient Safety 2Health News:New Patient Safety Proposed Regulation Aims to Improve Health Care Quality and Patient Safety 3Health News:New Patient Safety Proposed Regulation Aims to Improve Health Care Quality and Patient Safety 4Health News:Dental Devices Offer a Simple Solution for Sleep 2Health News:Dental Devices Offer a Simple Solution for Sleep 3
... to do the exams you want: ,Four probe ... the easiest water path probe in the industry, ... exactly what you need to. From full ... chamber, the P60 provides the clarity of images ...
... will find the samaritan AED easy ... medical and rescue professionals) will appreciate ... manual override, and the ECG monitoring ... AED is an exceptionally well-engineered, lightweight ...
... extraordinary combination of features make the ... multi-specialty clinical environment. The versatility and ... hardware allows you to perform a ... high-quality results., ,The ideal choice for ...
Assay for Anti-HTLV-I and Anti-HTLV-II...
Medicine Products: